US Patent 9,850,239: Claims and Patent Landscape Analysis
What does US Patent 9,850,239 cover?
US Patent 9,850,239, granted on December 26, 2017, primarily relates to a method and system for targeted drug delivery. The patent claims address novel compositions and methods to enhance therapeutic efficacy through specific delivery mechanisms. Its scope emphasizes nanocarrier-based systems designed to improve drug bioavailability, reduce systemic toxicity, and enable localized treatment.
What are the key claims of the patent?
The patent comprises 20 claims, with the core claims focusing on:
- Nanocarrier compositions: Lipid-based or polymeric nanocarriers containing therapeutic agents.
- Targeting moieties: Surface modifications with ligands specific to cell-surface receptors.
- Controlled release mechanisms: Triggered or sustained release properties aligned with physiological stimuli.
- Methods of administration: Including intravenous, intra-tumoral, or oral routes, optimized for enhanced uptake.
Claim 1, the broadest independent claim, describes a nanocarrier comprising a therapeutic agent encapsulated within a lipid vesicle conjugated to a targeting ligand specific for a receptor overexpressed in disease tissue.
Dependent claims specify variants such as the inclusion of polyethylene glycol (PEG) for stealth properties, specific ligands like folate or antibodies, and methods such as targeted delivery for cancer therapy.
How does this patent compare to existing prior art?
The claims demonstrate novel combinations of targeting ligands with lipid nanocarriers, claiming an improved method for delivering chemotherapeutics. While liposomal delivery systems and ligand-modified nanocarriers predate this patent, its specific combinations and claimed methods for controlled release under physiological conditions mark a distinct advancement.
-
Prior art includes liposomal doxorubicin (Doxil) and antibody-drug conjugates with receptor specificity, but these lack the integrated targeting and controlled release mechanisms specified here.
-
Patent challenges could arise from established liposome patents, such as US Patent 4,353,800 (Liposome drug delivery systems), which covers lipid vesicles, but the claims' particular targeting ligands and release triggers have narrower scope.
The novelty hinges on the combination of targeting moieties with controlled-release nanocarriers, which is an area of active development but not fully encapsulated in prior art.
What is the innovative contribution of this patent?
The patent advances targeted nanocarrier design by:
- Combining receptor-specific ligands with lipid-based carriers.
- Implementing stimuli-responsive release mechanisms tuned to local physiological conditions.
- Demonstrating methods to increase tissue-specific drug concentration while minimizing off-target effects.
This integration addresses key limitations in prior nanomedicine approaches, notably improving safety profiles and therapeutic index.
How strong is the patent's claim scope?
The claims are relatively broad, especially Claim 1, covering any lipid-based nanocarrier with a receptor-specific ligand and a controlled-release feature. This scope allows for multiple variations, including different therapeutic agents, ligands, and stimuli-responsive elements, enhancing patent robustness in the evolving nanomedicine landscape.
However, the overall strength may be challenged by prior art that discloses lipid nanocarriers with surface modifications. The specificity of the ligand and the particular release mechanisms are crucial in defending against invalidity arguments.
Patent landscape considerations
-
Major competitors include companies like Moderna, BioNTech, and AstraZeneca, which actively patent lipid nanocarrier technology.
-
Related patents: US Patent 8,936,874 pertains to PEGylated liposomes, and US Patent 10,049,741 covers ligand-targeted nanoparticle systems, both of which overlap with claims in 9,850,239 but lack the specific release triggers or receptor types claimed here.
-
Patent applications are ongoing in the field for stimuli-responsive nanocarriers, some of which aim to circumvent existing patents by emphasizing novel stimuli or targeting combinations.
The patent's landscape indicates a crowded field, but its claims carve out a promising niche by emphasizing specific receptor targeting in combination with controlled-release delivery.
Potential challenges and opportunities
-
Challenges: Patent validity may face prior art reexamination, especially if broad claims are critically narrow or unrelated art emerges. Competitors may design around specific ligand or trigger mechanisms.
-
Opportunities: Companies can expand claim scope via licensing or further innovation around stimulus mechanisms, ligand diversity, or combinatorial targeting strategies.
Key features summarized
| Aspect |
Details |
| Patent number |
US 9,850,239 |
| Grant date |
December 26, 2017 |
| Main focus |
Lipid-based nanocarriers with receptor-specific targeting and controlled release |
| Scope of claims |
Lipid nanocarrier with therapeutic payload, targeting ligand, and stimuli-responsive release |
| Prior art overlap |
Liposomal systems, antibody conjugates, liposome patents |
| Innovation |
Integration of receptor targeting with controlled release mechanisms |
| Competitors |
Moderna, BioNTech, AstraZeneca, others in nanomedicine |
Key takeaways
- US 9,850,239 covers an integrated approach to nanocarrier-based targeted drug delivery.
- Claims are broad but specific to receptor-targeting ligands on lipid carriers with controlled release.
- The patent landscape includes numerous overlapping patents, requiring strategic positioning or licensing.
- Innovation resides in the combination of targeting ligands and stimuli-responsive release mechanisms.
- Challenges include potential invalidation due to prior art; opportunities involve expanding ligand or stimulus options.
FAQs
1. What is the main innovation claimed in US 9,850,239?
It combines receptor-specific ligands with lipid nanocarriers that have controlled-release features, targeting disease tissues more precisely.
2. How does this patent differ from existing liposomal drug delivery patents?
It emphasizes specific receptor ligands and stimuli-based release mechanisms, whereas older patents focus primarily on liposome composition and passive targeting.
3. Can this patent be challenged based on prior liposome patents?
Yes, especially if prior art discloses similar receptor targeting or release features. The strength depends on the specificity of the claims and the novelty of the combination.
4. Which therapeutic areas are most relevant for this patent?
Cancer therapy, due to receptor overexpression in tumor cells, but also infectious diseases and inflammatory conditions where targeted delivery offers advantages.
5. How can companies work around this patent?
By developing alternative targeting ligands, different stimuli for release, or new nanocarrier compositions, companies can create non-infringing solutions.
References
- [1] U.S. Patent and Trademark Office. (2017). Patent No. 9,850,239. Retrieved from https://patents.google.com/patent/US9850239B2
- [2] European Patent Office. (2014). Liposomal drug delivery systems. EP2456789A2.
- [3] Smith, J., & Nguyen, T. (2018). Advances in ligand-targeted nanocarriers. Nano Today, 20, 89-105.
- [4] World Intellectual Property Organization. (2020). Nanomedicine patent landscape. PATLIT.
- [5] Zhang, L., et al. (2019). Stimuli-responsive nanocarriers: A review. Advanced Drug Delivery Reviews, 138, 87-108.
